Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cell Therapeutics, Inc. released updated 18–month follow–up clinical data for its phase III EXTEND trial of pixantrone for patients with advanced, relapsed or refractory, aggressive non–Hodgkin's lymphoma. Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address